Safety Evaluation of Intra-Abdominal Implantation of Sustained-Releasing 5-Fluorouracil in Gastrointestinal Malignant Tumor_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

LIU Liu ¹ , ZHUANG Wen ¹ , CHEN Zhong ² , CHEN Bo ¹

1.Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China;;
2.Department of Paediatrics, West China Second University Hospital, Sichuan University, Chengdu 610041, China;

Corresponding author：

Keywords：

Gastric cancer; Colorectal cancer; Sustained-releasing 5-fluorouracil; Safety; Complication

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the postoperative influence of intra-abdominal implantation of sustained-releasing 5fluorouracil on the hepato-renal function, immune function, nutritional state and complications in patients with gastric and colorectal cancer.
Methods Sixty-five patients with gastric or colorectal cancer were included into this study from January to June 2009. The patients (35 cases of gastric cancer, 18 cases of colon cancer and 12 cases of rectal cancer) were randomly divided into experimental group (n=25) and control group (n=40). In experimental group, 400 mg sustained-releasing 5-fluorouracil was used. Blood samples were gained before operation, the second day and the seventh day after operation to examine the indexes of hepato-renal function, immune function and nutritional state. Complications， venting time and length of stay after operation were also recorded.
Results There was no statistical significance for distribution of tumor stages and patients’ gender between experimental group and control group (P gt;0.05). Preoperative indexes of hepato-renal function, immune function and nutritional state were also not reached statistical significance between two groups (P gt;0.05). Compared with control group, the indexes of total protein and transferrin were decreased and urea nitrogen and IgM were increased in the second day after operation in experimental group (P lt;0.05). The number of lymphocyte was increased, while CD4, Alb, total protein and IgA were decreased in the seventh day after operation in experimental group, respectively. The time of passage of gas of experimental group was longer than that of control group (P lt;0.05).
Conclusion Intra-abdominal implantation of sustained-releasing 5-fluorouracil is safe and feasible, which does not increase the complications and the time of length stay after operation. However, there is a little influence on immune function and gastrointestinal function after operation for intra-abdominal implantation of sustained-releasing 5-fluorouracil.

Citation： LIU Liu ,ZHUANG Wen,CHEN Zhong,CHEN Bo. Safety Evaluation of Intra-Abdominal Implantation of Sustained-Releasing 5-Fluorouracil in Gastrointestinal Malignant Tumor. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2010, 17(2): 170-174. doi: Copy

1.	Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin, 2005; 55(2): 74108.
2.	Sanjoaquin MA, ChoodariOskooei B, Dolbear C, et al. Colorectal cancer incidence, mortality and survival in Southeast England between 1972 and 2001 [J]. Eur J Cancer Prev, 2007; 16(1): 1016.
3.	丁松涛, 张忠涛. 胃癌腹膜转移的研究现状和进展 [J]. 国际外科学杂志, 2006; 33(6): 414418.
4.	Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma [J]. Br J Surg, 2000; 87(2): 236242.
5.	Parkin DM, Olsen AH, Sasieni P. The potential for prevention of colorectal cancer in the UK [J]. Eur J Cancer Prev, 2009; 18(3): 179190.
6.	黄莚庭. 大肠癌诊治现状与展望 [J]. 中国普外基础与临床杂志, 2000; 7(1): 4445.
7.	陈威佐, 陈文元, 罗好曾. 武威市2001~2005年胃癌发病率分析 [J]. 中国肿瘤, 2007; 16(5): 309310.
8.	陈佳平. 胃癌术后复发的诊断与治疗 [J]. 中国普外基础与临床杂志, 2004; 11(2): 104106.
9.	何运胜，姜淮芜. 进展期胃癌多模式治疗的研究进展 [J]. 中国普外基础与临床杂志, 2008; 15(1): 3135.
10.	Tsujitani S, Oka S, Suzuki K, et al. Prognostic factors in patients with advanced gastric cancer treated by noncurative resection: a multivariate analysis [J]. Hepatogastroenterology, 2001; 48(41): 15041508.
11.	何涛，杨志明，伍晓汀. 胃癌腹膜播散转移机理的研究进展 [J]. 中国普外基础与临床杂志, 2005; 12(1): 4345.
12.	Wu CW, Lo SS, Shen KH, et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer [J]. World J Surg, 2003; 27(2): 153158.
13.	徐大志, 耿其荣, 林桐榆, 等. 腹腔化疗在进展期胃癌根治术后的的治疗作用新评价 [J]. 第四军医大学学报, 2009; 30(5): 443446.
14.	Lefevre JH, Elias DM. Cytoreductive surgery plus intraperitoneal chemohyperthermia in patients with colorectal cancer at high risk for localregional recurrence [J]. Cancer J, 2009; 15(3): 200203.
15.	朱莉菲, 黄伟翼, 陈栋晖, 等. 进展期胃癌术后早期腹腔温热灌注化疗疗效的临床研究 [J]. 中国肿瘤, 2008; 17(9): 810812.
16.	魏国, 毕建威, 申晓军, 等. 中晚期胃癌术中腹腔内植入氟尿嘧啶缓释剂37例 [J]. 中国肿瘤, 2007; 16(4): 286288.
17.	李沛雨. 直肠癌病人术中植入5氟尿嘧啶缓释剂的安全性及疗效研究 [J]. 外科理论与实践, 2009; 14(1): 5254.
18.	杜卫东, 袁祖荣, 倪泉兴, 等. 5氟尿嘧啶缓释剂瘤内注射治疗胰腺癌的实验研究和临床研究 [J]. 中国普通外科杂志, 2005; 14(5): 355360.
19.	周益龙, 蒋松琪, 黄建, 等. 直肠癌根治术中植入5氟尿嘧啶缓释剂45例临床研究 [J]. 南通大学学报(医学版), 2007; 27(6): 520521.
20.	吴海静, 张国楠. 化疗的副反应及其防治 [J]. 中国实用妇科与产科杂志, 2008; 24(9): 667669.
21.	江洪, 周星明, 严福来, 等. 食管癌术中植入5氟尿嘧啶缓释剂的安全性 [J]. 中国肿瘤, 2006; 15(4): 262264.

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin, 2005; 55(2): 74108.
2. Sanjoaquin MA, ChoodariOskooei B, Dolbear C, et al. Colorectal cancer incidence, mortality and survival in Southeast England between 1972 and 2001 [J]. Eur J Cancer Prev, 2007; 16(1): 1016.
3. 丁松涛, 张忠涛. 胃癌腹膜转移的研究现状和进展 [J]. 国际外科学杂志, 2006; 33(6): 414418.
4. Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma [J]. Br J Surg, 2000; 87(2): 236242.
5. Parkin DM, Olsen AH, Sasieni P. The potential for prevention of colorectal cancer in the UK [J]. Eur J Cancer Prev, 2009; 18(3): 179190.
6. 黄莚庭. 大肠癌诊治现状与展望 [J]. 中国普外基础与临床杂志, 2000; 7(1): 4445.
7. 陈威佐, 陈文元, 罗好曾. 武威市2001~2005年胃癌发病率分析 [J]. 中国肿瘤, 2007; 16(5): 309310.
8. 陈佳平. 胃癌术后复发的诊断与治疗 [J]. 中国普外基础与临床杂志, 2004; 11(2): 104106.
9. 何运胜，姜淮芜. 进展期胃癌多模式治疗的研究进展 [J]. 中国普外基础与临床杂志, 2008; 15(1): 3135.
10. Tsujitani S, Oka S, Suzuki K, et al. Prognostic factors in patients with advanced gastric cancer treated by noncurative resection: a multivariate analysis [J]. Hepatogastroenterology, 2001; 48(41): 15041508.
11. 何涛，杨志明，伍晓汀. 胃癌腹膜播散转移机理的研究进展 [J]. 中国普外基础与临床杂志, 2005; 12(1): 4345.
12. Wu CW, Lo SS, Shen KH, et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer [J]. World J Surg, 2003; 27(2): 153158.
13. 徐大志, 耿其荣, 林桐榆, 等. 腹腔化疗在进展期胃癌根治术后的的治疗作用新评价 [J]. 第四军医大学学报, 2009; 30(5): 443446.
14. Lefevre JH, Elias DM. Cytoreductive surgery plus intraperitoneal chemohyperthermia in patients with colorectal cancer at high risk for localregional recurrence [J]. Cancer J, 2009; 15(3): 200203.
15. 朱莉菲, 黄伟翼, 陈栋晖, 等. 进展期胃癌术后早期腹腔温热灌注化疗疗效的临床研究 [J]. 中国肿瘤, 2008; 17(9): 810812.
16. 魏国, 毕建威, 申晓军, 等. 中晚期胃癌术中腹腔内植入氟尿嘧啶缓释剂37例 [J]. 中国肿瘤, 2007; 16(4): 286288.
17. 李沛雨. 直肠癌病人术中植入5氟尿嘧啶缓释剂的安全性及疗效研究 [J]. 外科理论与实践, 2009; 14(1): 5254.
18. 杜卫东, 袁祖荣, 倪泉兴, 等. 5氟尿嘧啶缓释剂瘤内注射治疗胰腺癌的实验研究和临床研究 [J]. 中国普通外科杂志, 2005; 14(5): 355360.
19. 周益龙, 蒋松琪, 黄建, 等. 直肠癌根治术中植入5氟尿嘧啶缓释剂45例临床研究 [J]. 南通大学学报(医学版), 2007; 27(6): 520521.
20. 吴海静, 张国楠. 化疗的副反应及其防治 [J]. 中国实用妇科与产科杂志, 2008; 24(9): 667669.
21. 江洪, 周星明, 严福来, 等. 食管癌术中植入5氟尿嘧啶缓释剂的安全性 [J]. 中国肿瘤, 2006; 15(4): 262264.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Safety Evaluation of Intra-Abdominal Implantation of Sustained-Releasing 5-Fluorouracil in Gastrointestinal Malignant Tumor

Abstract Full text Figures/Tables Video References Cited by

Format

Content